BBIO — BRIDGEBIO PHARMA INC

Ownership history in STEMPOINT CAPITAL LP  ·  5 quarters on record

This page tracks every 13F SEC filing in which STEMPOINT CAPITAL LP reported a position in BRIDGEBIO PHARMA INC (BBIO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
2.74% (2023 Q4)
Avg. % of fund
1.57%
First filed
2023 Q4
Last filed
2025 Q3
Quarters held
5
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 127,435 +72,805 +133.3% 1.33% $6.6M $51.94
2025 Q2 REDUCED 54,630 -153,807 -73.8% 0.76% $2.4M $43.18
2025 Q1 ADDED 208,437 +113,552 +119.7% 2.30% $7.2M $34.57
2024 Q3 REDUCED 94,885 -159,063 -62.6% 0.72% $2.4M $25.46
2023 Q4 INITIATED 253,948 — — 2.74% $10.3M —
% of Fund (quarterly)    BBIO price (monthly, adj. close)

Other funds also holding BBIO

As of 2025 Q4 — sorted by position size

Aisling Capital Management LP 3Y 7Y 81.29% Kohlberg Kravis Roberts & Co. L.P. 3Y 7Y 16.22% Frazier Life Sciences Management, L.P. 3Y 7.28% First Turn Management, LLC 5.2% BOONE CAPITAL MANAGEMENT LLC 3Y 4.44% Eagle Health Investments LP 3Y 4.36% Monashee Investment Management LLC 3Y 7Y 4.31% Cormorant Asset Management, LP 3Y 7Y 4.24% Atle Fund Management AB 3Y 7Y 3.45% Laurion Capital Management LP 3Y 7Y 3.28%
← Back to STEMPOINT CAPITAL LP Holdings